Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Medication Guide

Firocoxib

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Chewable Tablets Multiple FDA sponsors Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Sep 20, 2026, 10:00 a.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Sep 20, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Sep 8, 2026, 10:02 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Sep 20, 2026, 10:00 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Sep 20, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Mar 3, 2026, 11:00 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed Sep 20, 2026, 10:05 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Sep 20, 2026, 10:05 AM UTC
Illustration placeholder
Firocoxib

Firocoxib

Drug type: Generic ingredient • Generic profile • No FDA branded products linked

Both Chewable Tablets Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA sponsors

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Firocoxib

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs. For the control of pain and inflammation associated with osteoarthritis. For the control of pain and inflammation associated with osteoarthritis in horses. Species commonly shown: Both, Dog, Horse, Not For Meat Production.

Generic name
Firocoxib
Brand names
Previcox®, Equioxx® Oral Paste, Equioxx® Injection, Equioxx®
Manufacturer
Multiple FDA sponsors
Species
Both, Dog, Horse
Dosage forms
Chewable Tablets, Paste, Non-Aqueous Injectable Solution, Tablet
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Previcox® Equioxx® Oral Paste Equioxx® Injection Equioxx® Firox™ Firocoxib Tablets for Horses Firocoxib Chewable Tablets for Dogs Firocoxib Firodyl™ EquiCoxib®
Dosage forms
Chewable Tablets Paste Non-Aqueous Injectable Solution Tablet Oral Solution

Indications / Uses

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs. For the control of pain and inflammation associated with osteoarthritis. For the control of pain and inflammation associated with osteoarthritis in horses.

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intravenous use in horses only.

  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intravenous use in horses only.

Side Effects

Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Diarrhoea, Elevated blood urea nitrogen (BUN), Other abnormal test result NOS, Elevated creatinine.

FAQ

Both, Dog, Horse, Not For Meat Production

Yes. Roxee shows this as prescription-only.

Chewable Tablets, Paste, Non-Aqueous Injectable Solution, Tablet

Related Conditions

Osteoarthritis (Degenerative Joint Disease) Osteoarthritis (Degenerative Joint Disease) Pain (acute, chronic)

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the control of pain and inflammation associated with osteoarthritis.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Do not use in horses intended for human consumption
  • For intravenous use in horses only
  • Vomiting (1 reports)
  • wobbly/unsteady walking (1 reports)
  • Loss of appetite (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence
Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Firocoxib; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case DEU-USFDACVM-2025-DE-000039
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 27 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case DEU-USFDACVM-2025-DE-000039
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case DEU-USFDACVM-2025-DE-000039
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Vomiting (1 reports), Unsteady walking (ataxia) (1 reports), Loss of appetite (1 reports), Hyperphosphataemia (1 reports), Horizontal nystagmus (1 reports)

Body systems represented Signal grouping

Digestive (4), Neurologic (2), Other (26)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (27 reports), Cat (5 reports)

Breed metadata in reports Metadata only

Retriever - Labrador (2), ['Ridgeback - Rhodesian', 'Dog (unknown)'] (1), Pit Bull (1), Bulldog - French (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Firocoxib fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Do not use in horses intended for human consumption, For intravenous use in horses only, Vomiting, wobbly/unsteady walking, Loss of appetite

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Firocoxib brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case DEU-USFDACVM-2025-DE-000039 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. FDA application profile · official_label · quick facts
  5. Medication usage source · fda_animal_drugs · quick facts
  6. FOI · document · documents
  7. SPL · document · documents
  8. FOI · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • Do not use in horses intended for human consumption
  • For intravenous use in horses only
  • Vomiting
  • wobbly/unsteady walking
  • Loss of appetite

Most reported reactions:

  • Vomiting (1 reports)
  • Unsteady walking (ataxia) (1 reports)
  • Loss of appetite (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Dog, Horse
Indication / use
For the control of pain and inflammation associated with osteoarthritis.
Form / route / dose
Form: Chewable Tablets, Non-Aqueous Injectable Solution, Oral Solution, Paste, Tablet
Route: Intravenous, Oral
Confirm product label and patient-specific plan.
Warnings
  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for…
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA sponsors
Form: Chewable Tablets, Non-Aqueous Injectable Solution, Oral Solution, Paste, Tablet
Identifiers:
ANADA: 200722 ANADA: 200726 ANADA: 200751 ANADA: 200755 ANADA: 200756 ANADA: 200766 ANADA: 200841 NADA: 141230 NADA: 141253 NADA: 141313 NADA: 141458 NDC Package: 0010-3309-01 NDC Package: 0010-3309-02 NDC Package: 0010-9140-02 NDC Package: 0010-9140-03 NDC Package: 0010-9140-06 NDC Package: 0010-9150-02 NDC Package: 0010-9150-03 NDC Package: 0010-9150-05 NDC Package: 11695-7018-1
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intravenous use in horses only.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intravenous use in horses only.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
13
Matching reports
4
Active filters
1
Selected filters
Body system: Neurologic Clear
Reset
Drill into common report signals
Death by euthanasia (3) Vomiting (3) Weakness (3) Agitation (2) Other (11) Digestive (6) Neurologic (4) Skin & allergy (1)
Showing up to 50 matching reports.

USA-USFDACVM-2026-US-006296

Received 2026-02-13 · MSK · MSK

Serious
Species
Dog
Breed
['Collie - Border', 'Dog (unknown)']
Size / weight
50-99 lb (27.578 Kilogram)
Age
8+ years (14.4 Year)
Sex
Female Unknown
Region
USA
Reactions
Infectious disease NOSLow thyroxine (T4)Elevated liver enzymes NOSHead tilt - neurological disorder (see also Head tilt - ear disorder)Unsteady gaitVestibular disorder NOSAnorexiaAdipsiaHorizontal nystagmusSick euthyroid syndromeNeutrophilia
Body systems
OtherNeurologicDigestive
Outcomes
Ongoing

USA-USFDACVM-2026-US-006186

Received 2026-02-13 · MSK · MSK

Serious
Species
Dog
Breed
['Retriever - Labrador', 'Poodle (unspecified)']
Size / weight
50-99 lb (31.751 Kilogram)
Age
8+ years (8 Year)
Sex
Female Unknown
Region
USA
Reactions
Tremor of limbUnsteady gaitTorn ligamentTendon ruptureMedication error NOSLameness
Body systems
NeurologicOther
Outcomes
Ongoing

USA-USFDACVM-2025-US-073418

Received 2025-11-24 · MSK · MSK

Serious
Species
Dog
Breed
['Boxer (German Boxer)', 'Dog (other)']
Size / weight
25-49 lb (21.047 Kilogram)
Age
8+ years (1 Year)
Sex
Male Neutered
Region
USA
Reactions
Musculoskeletal disorder NOSAtaxiaWeaknessAgitationPantingDeath by euthanasia
Body systems
OtherNeurologic
Outcomes
Euthanized

USA-USFDACVM-2025-US-065912

Received 2025-10-31 · MSK · MSK

Serious
Species
Dog
Breed
['Boxer (German Boxer)', 'Retriever (unspecified)', 'Bulldog - English']
Size / weight
25-49 lb (21.047 Kilogram)
Age
8+ years (1 Year)
Sex
Male Neutered
Region
USA
Reactions
Musculoskeletal disorder NOSAtaxiaWeaknessAgitationPantingDeath by euthanasia
Body systems
OtherNeurologic
Outcomes
Euthanized

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
27
Species represented
2
Grouped by Body System
Digestive (4) · Vomiting, Loss of appetite, Diarrhea Neurologic (2) · Unsteady walking (ataxia), Head tilt - neurological disorder Other (26) · Hyperphosphataemia, Horizontal nystagmus, Hind limb paralysis
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Digestive 1 Dog 1
Neurologic 1 Dog 1
Digestive 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Neurologic 1 Dog 1
Other 1 Dog 1

Species coverage: Dog (27) Cat (5)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Dog Serious - 1
Neurologic Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Neurologic Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Digestive Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

A-200766-C-0004-NL-AA_PI.pdf Official label / PI · Labeling A-200766-C-0002-CP-AA_CIS.pdf Official label / PI · Labeling A-200755-G-0020-FL-AA_CIS.pdf Official label / PI · Labeling

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

15

SPL

11

FOI

13

A-200766-C-0004-NL-AA_PI.pdf

Official label / PI · Labeling

Open original

A-200766-C-0002-CP-AA_CIS.pdf

Official label / PI · Labeling

Open original

A-200755-G-0020-FL-AA_CIS.pdf

Official label / PI · Labeling

Open original

A-200755-G-0020-FL-AA_PI.pdf

Official label / PI · Labeling

Open original

N-141230-C-0093-NL-AA_CIS.pdf

Official label / PI · Labeling

Open original

N-141230-C-0093-NL-AA_PI.pdf

Official label / PI · Labeling

Open original

A-200751-G-0002-FL-AA_PI.pdf

Official label / PI · Labeling

Open original

A-200722-G-0004-FL-AA_CIS.pdf

Official label / PI · Labeling

Open original

FIROX TABLETS 227mg 180x LBL.pdf

Official label / PI · Labeling

Open original

N-141253-C-0057-NL-AA_CIS.pdf

Official label / PI · Labeling

Open original

N-141253-C-0057-NL-AA_PI.pdf

Official label / PI · Labeling

Open original

N-141458-C-0015-NL-AA_CIS.pdf

Official label / PI · Labeling

Open original

N-141458-C-0015-NL-AA_PI.pdf

Official label / PI · Labeling

Open original

UCM422151.pdf

Official label / PI · Labeling

Open original

UCM422171.pdf

Official label / PI · Labeling

Open original

Firocoxib Tablets for Horses

SPL · SPL

Open original
FDA Structured Product Label

Firocoxib Tablets for Horses

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Felix Pharmaceuticals Pvt. Ltd.
ANADA
200-841
Status
RX
Form
Tablet
Route
Oral
Composition / specifications
57 mg firocoxib per tablet

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis.

Dosage

Administer one 57-mg tablet to horses weighing 800 to 1,300 lb once daily for up to 14 days.

EquiCoxib™

SPL · SPL

Open original
FDA Structured Product Label

EquiCoxib®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Aurora Pharmaceutical, Inc.
ANADA
200-766
Status
RX
Form
Oral Solution
Route
Oral
Composition / specifications
9.0 mg/mL

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis in horses.

Dosage

0.045 mg/lb (0.1 mg/kg) of body weight once daily for up to 14 days

Firodyl™

SPL · SPL

Open original
FDA Structured Product Label

Firodyl™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
ZyVet Animal Health, Inc.
ANADA
200-756
Status
RX
Form
Chewable Tablets
Route
Oral
Species
Dog
Composition / specifications
57 mg and 227 mg of firocoxib per tablet

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery.

Dosage

5 mg/kg (2.27 mg/lb) body weight. Administer once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Administer approximately 2 hours before soft-tissue or orthopedic surgery.

Firocoxib

SPL · SPL

Open original
FDA Structured Product Label

Firocoxib

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Felix Pharmaceuticals Pvt. Ltd.
ANADA
200-755
Status
RX
Form
Chewable Tablets
Route
Oral
Species
Dog
Composition / specifications
57 mg or 227 mg of firocoxib per tablet

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis; and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery.

Dosage

5 mg/kg (2.27 mg/lb) body weight. Administer once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Administer approximately 2 hours before soft-tissue or orthopedic surgery.

Previcox®

SPL · SPL

Open original
FDA Structured Product Label

Previcox®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA, Inc.
NADA
141-230
Status
RX
Form
Chewable Tablets
Route
Oral
Species
Dog
Composition / specifications
Each chewable tablet contains 57 or 227 mg firocoxib.

Dogs

Indication
For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs.
Dosage
5 mg/kg (2.27 mg/lb) body weight once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Administer approximately 2 hours prior to surgery.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Firocoxib Chewable Tablets for Dogs

SPL · SPL

Open original
FDA Structured Product Label

Firocoxib Chewable Tablets for Dogs

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Pegasus Laboratories, Inc.
ANADA
200-751
Status
RX
Form
Chewable Tablets
Route
Oral
Species
Dog
Composition / specifications
57 mg or 227 mg of firocoxib per tablet

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs.

Dosage

5 mg/kg (2.27 mg/lb) body weight. Administer once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Administer approximately 2 hours before soft-tissue or orthopedic surgery.

Firox™

SPL · SPL

Open original
FDA Structured Product Label

Firox™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Norbrook Laboratories, Ltd.
ANADA
200-722
Status
RX
Form
Chewable Tablets
Route
Oral
Species
Dog
Composition / specifications
57 mg and 227 mg of firocoxib per tablet

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs.

Dosage

2.27 mg/lb (5.0 mg/kg) body weight once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Administer approximately 2 hours prior to surgery.

Firocoxib Tablets for Horses

SPL · SPL

Open original
FDA Structured Product Label

Firocoxib Tablets for Horses

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Pegasus Laboratories, Inc.
ANADA
200-726
Status
RX
Form
Tablet
Route
Oral
Composition / specifications
57 mg firocoxib per tablet

Horses

Indication

For the control of pain and inflammation associated with osteoarthritis in horses.

Dosage

One 57 mg tablet administered orally to horses weighing 800 – 1300 lbs, once daily for up to 14 days.

Equioxx® Oral Paste

SPL · SPL

Open original
FDA Structured Product Label

Equioxx® Oral Paste

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA, Inc.
NADA
141-253
Status
RX
Form
Paste
Route
Oral
Species
Horse
Composition / specifications
Each milligram (mg) of paste contains 0.82 mg firocoxib.

Horses

Indication
For the control of pain and inflammation associated with osteoarthritis.
Dosage
0.1 mg per kilogram (0.045 mg per pound) body weight daily for up to 14 days.
Limitations
Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Equioxx®

SPL · SPL

Open original
FDA Structured Product Label

Equioxx®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA, Inc.
NADA
141-458
Status
RX
Form
Tablet
Route
Oral
Composition / specifications
57 mg firocoxib

Horses

Indication
For the control of pain and inflammation associated with osteoarthritis in horses.
Dosage
Administer one 57 mg tablet daily for horses weighing 800-1300 lbs for up to 14 days duration.
Limitations
For use in horses only. Do not use in horses intended for human consumption.

Equioxx® Injection

SPL · SPL

Open original
FDA Structured Product Label

Equioxx® Injection

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA, Inc.
NADA
141-313
Status
RX
Form
Non-Aqueous Injectable Solution
Route
Intravenous
Composition / specifications
20 mg firocoxib per mL

Horses

Indication
For the control of pain and inflammation associated with osteoarthritis in horses.
Dosage
One intravenous injection once daily for up to 5 days, at a dose of 0.04 mg/lb (0.09 mg/kg) body weight (BW). If further treatment is needed EQUIOXX (firocoxib) Oral Paste for horses can be used at a dosage of 0.045 mg/lb (0.1 mg/kg) body weight for up to an additional 9 days of treatment. The overall duration of treatment EQUIOXX Injection and EQUIOXX Oral Paste will be dependent on the response observed, but should not exceed 14 days.
Limitations
Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intravenous use in horses only.

FOI Summary oA 200-841 Approved February 23, 2026.pdf

FOI · FOI

Open original

FOI Summary oA 200-766 Approved January 11, 2024.pdf

FOI · FOI

Open original

FOI Summary oA 200-756 Approved August 3, 2023.pdf

FOI · FOI

Open original

FOI Summary oA 200-755 Approved August 3, 2023.pdf

FOI · FOI

Open original

UCM218719.pdf

FOI · FOI

Open original

ucm118042.pdf

FOI · FOI

Open original

ucm118041.pdf

FOI · FOI

Open original

FOI Summary oA 200-751 Approved June 22, 2023.pdf

FOI · FOI

Open original

FOI Summary oA 200-722 Approved March 28, 2022.pdf

FOI · FOI

Open original

FOI Summary oA 200-726 Approved July 29, 2022.pdf

FOI · FOI

Open original

UCM051453.pdf

FOI · FOI

Open original

UCM514663.pdf

FOI · FOI

Open original

UCM308268.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Sep 20, 2026, 10:00 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Sep 20, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Mar 3, 2026, 11:00 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed Sep 20, 2026, 10:05 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Sep 20, 2026, 10:05 AM UTC
Official (FDA)
Identity: Generic ingredient • No FDA branded products linked
No official FDA brand rows linked yet for this ingredient.
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Dog, Horse
Rx/OTC: RX
Form/route: Chewable Tablets, Non-Aqueous Injectable Solution, Oral Solution, Paste, Tablet • Intravenous, Oral
Applications: ANADA 200-841 • ANADA 200-766 • ANADA 200-756 • ANADA 200-755 • NADA 141-230 • ANADA 200-751 • ANADA 200-722 • ANADA 200-726 • NADA 141-253 • NADA 141-458 • NADA 141-313
Documents: 28 (FOI: 13) • SPL: 11 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 40 • Cat 0 • View
Case summaries: 13 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes
ICD10_CM: M19.90
Unspecified osteoarthritis, unspecified site

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intravenous use in horses only. (Contraindication, High)
Top reaction signals
Vomiting (1) Unsteady walking (ataxia) (1) Loss of appetite (1) Hyperphosphataemia (1) Horizontal nystagmus (1) Hind limb paralysis (1) Head tilt - neurological disorder (1) Haematuria (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200722 ANADA: 200726 ANADA: 200751 ANADA: 200755 ANADA: 200756 ANADA: 200766 ANADA: 200841 NADA: 141230 NADA: 141253 NADA: 141313 NADA: 141458 NDC Package: 0010-3309-01 NDC Package: 0010-3309-02 NDC Package: 0010-9140-02 NDC Package: 0010-9140-03 NDC Package: 0010-9140-06 NDC Package: 0010-9150-02 NDC Package: 0010-9150-03 NDC Package: 0010-9150-05 NDC Package: 11695-7018-1 NDC Package: 11695-7018-2 NDC Package: 11695-7019-1 NDC Package: 11695-7019-2 NDC Package: 11695-7064-1
Package NDC Product NDC Form / Route Status
0010-3309-01 0010 -
0010-3309-02 0010 -
0010-9140-02 0010 -
0010-9140-03 0010 -
0010-9140-06 0010 -
0010-9150-02 0010 -
0010-9150-03 0010 -
0010-9150-05 0010 -
11695-7018-1 11695 -
11695-7018-2 11695 -
11695-7019-1 11695 -
11695-7019-2 11695 -
11695-7064-1 11695 -
11695-7064-2 11695 -
11695-7065-1 11695 -
11695-7065-2 11695 -
11695-7066-1 11695 -
11695-7066-2 11695 -
17033-720-18 17033 -
17033-720-60 17033 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 147 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Diarrhoea, Elevated blood urea nitrogen (B… (Clinical, 2026-04-11)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restrict… (Official, 2026-04-12)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restrict… (Official, 2026-04-11)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restrict… (Official, 2026-02-12)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-20)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-19)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-18)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-17)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-16)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-15)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-14)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-13)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-12)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-11)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-10)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-09)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-08)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-07)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-06)
  • indications: EQUIOXX Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses. For the control of pain… (Official, 2026-09-05)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Firocoxib Tablets for Horses
RX
Firocoxib
Tablet • Oral
Label highlights
Official documents
Felix Pharmaceuticals Pvt. Ltd. ANADA 200-841 Approved Aug 13, 2026
EquiCoxib®
RX
Firocoxib
Oral Solution • Oral
Label highlights
Official documents
Aurora Pharmaceutical, Inc. ANADA 200-766 Approved Jul 20, 2026
Firodyl™
RX
Firocoxib
Chewable Tablets • Oral
Label highlights
Official documents
ZyVet Animal Health, Inc. ANADA 200-756 Approved Jul 20, 2026
Firocoxib
RX
Firocoxib
Chewable Tablets • Oral
Label highlights
Official documents
Felix Pharmaceuticals Pvt. Ltd. ANADA 200-755 Approved Apr 24, 2025
Previcox®
RX
Firocoxib
Chewable Tablets • Oral
Label highlights
Official documents
Boehringer Ingelheim Animal Health USA, Inc. NADA 141-230 Approved Apr 24, 2025
Firocoxib Chewable Tablets for Dogs
RX
Firocoxib
Chewable Tablets • Oral
Label highlights
Official documents
Pegasus Laboratories, Inc. ANADA 200-751 Approved Mar 4, 2024
Firox™
RX
Firocoxib
Chewable Tablets • Oral
Label highlights
Official documents
Norbrook Laboratories, Ltd. ANADA 200-722 Approved Nov 2, 2022
Firocoxib Tablets for Horses
RX
Firocoxib
Tablet • Oral
Label highlights
Official documents
Pegasus Laboratories, Inc. ANADA 200-726 Approved Aug 1, 2022
Equioxx® Oral Paste
RX
Firocoxib
Paste • Oral
Label highlights
Official documents
Boehringer Ingelheim Animal Health USA, Inc. NADA 141-253 Approved Apr 8, 2020
Equioxx®
RX
Firocoxib
Tablet • Oral
Label highlights
Official documents
Boehringer Ingelheim Animal Health USA, Inc. NADA 141-458 Approved Dec 17, 2019
Equioxx® Injection
RX
Firocoxib
Non-Aqueous Injectable Solution • Intravenous
Label highlights
Official documents
Boehringer Ingelheim Animal Health USA, Inc. NADA 141-313 Approved Nov 13, 2017

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications
57 mg firocoxib per tablet
Horses
Indication

For the control of pain and inflammation associated with osteoarthritis.

Dosage

Administer one 57-mg tablet to horses weighing 800 to 1,300 lb once daily for up to 14 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Composition / specifications
9.0 mg/mL
Horses
Indication

For the control of pain and inflammation associated with osteoarthritis in horses.

Dosage

0.045 mg/lb (0.1 mg/kg) of body weight once daily for up to 14 days

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog
Composition / specifications
57 mg and 227 mg of firocoxib per tablet
Dogs
Indication

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery.

Dosage

5 mg/kg (2.27 mg/lb) body weight. Administer once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Administer approximately 2 hours before soft-tissue or orthopedic surgery.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog
Composition / specifications
57 mg or 227 mg of firocoxib per tablet
Dogs
Indication

For the control of pain and inflammation associated with osteoarthritis; and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery.

Dosage

5 mg/kg (2.27 mg/lb) body weight. Administer once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Administer approximately 2 hours before soft-tissue or orthopedic surgery.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog
Composition / specifications
Each chewable tablet contains 57 or 227 mg firocoxib.
Dogs
Indication
For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs.
Dosage
5 mg/kg (2.27 mg/lb) body weight once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Administer approximately 2 hours prior to surgery.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog
Composition / specifications
57 mg or 227 mg of firocoxib per tablet
Dogs
Indication

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs.

Dosage

5 mg/kg (2.27 mg/lb) body weight. Administer once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Administer approximately 2 hours before soft-tissue or orthopedic surgery.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog
Composition / specifications
57 mg and 227 mg of firocoxib per tablet
Dogs
Indication

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs.

Dosage

2.27 mg/lb (5.0 mg/kg) body weight once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Administer approximately 2 hours prior to surgery.

Limitations

FDA page: Open in Animal Drugs @ FDA

Composition / specifications
57 mg firocoxib per tablet
Horses
Indication

For the control of pain and inflammation associated with osteoarthritis in horses.

Dosage

One 57 mg tablet administered orally to horses weighing 800 – 1300 lbs, once daily for up to 14 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Horse
Composition / specifications
Each milligram (mg) of paste contains 0.82 mg firocoxib.
Horses
Indication
For the control of pain and inflammation associated with osteoarthritis.
Dosage
0.1 mg per kilogram (0.045 mg per pound) body weight daily for up to 14 days.
Limitations
Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Composition / specifications
57 mg firocoxib
Horses
Indication
For the control of pain and inflammation associated with osteoarthritis in horses.
Dosage
Administer one 57 mg tablet daily for horses weighing 800-1300 lbs for up to 14 days duration.
Limitations
For use in horses only. Do not use in horses intended for human consumption.

FDA page: Open in Animal Drugs @ FDA

Composition / specifications
20 mg firocoxib per mL
Horses
Indication
For the control of pain and inflammation associated with osteoarthritis in horses.
Dosage
One intravenous injection once daily for up to 5 days, at a dose of 0.04 mg/lb (0.09 mg/kg) body weight (BW). If further treatment is needed EQUIOXX (firocoxib) Oral Paste for horses can be used at a dosage of 0.045 mg/lb (0.1 mg/kg) body weight for up to an additional 9 days of treatment. The overall duration of treatment EQUIOXX Injection and EQUIOXX Oral Paste will be dependent on the response observed, but should not exceed 14 days.
Limitations
Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intravenous use in horses only.

FDA page: Open in Animal Drugs @ FDA

Usage

For the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs. For the control of pain and inflammation associated with osteoarthritis. For the control of pain and inflammation associated with osteoarthritis in horses.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intravenous use in horses only.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Vomiting (1) • Dog Loss of appetite (1) • Dog Diarrhea (1) • Dog Bloody diarrhoea (1) • Dog

Showing top 5 for Digestive.

Neurologic
Unsteady walking (1) • Dog Head tilt - neurological disorder (1) • Dog

Showing top 5 for Neurologic.

Other
Hyperphosphataemia (1) • Dog Horizontal nystagmus (1) • Dog Hind limb paralysis (1) • Dog Haematuria (1) • Dog Gastric ulcer (1) • Dog
Show more (21)
Fluid in abdomen NOS (1) • Dog Faecal incontinence (1) • Dog Facial paralysis (1) • Dog Facial palsy (1) • Dog Elevated liver enzymes NOS (1) • Cat Elevated creatinine (1) • Dog Elevated blood urea nitrogen (1) • Dog Dry heaving (1) • Dog Distension of abdomen (1) • Dog Death by euthanasia (1) • Cat Death (1) • Dog Cold feeling of extremity (1) • Cat Bone and joint disorder NOS (1) • Dog Bloated (1) • Dog Agitation (1) • Dog Administration error NOS (1) • Cat Adipsia (1) • Dog Accidental exposure (1) • Cat Abnormal ultrasound finding (1) • Dog Abnormal radiograph finding (1) • Dog Abdominal pain (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Retriever - Labrador, Male, 10 year, 42.003 kilogram • Drug: MSK, Tablet, chewable, Unknown • Reactions: Weakness, Medication error NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-011394
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 10.00 Year
  • Weight: 42.003 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Tablet, chewable
Reactions Reported:
Weakness Medication error NOS
Outcomes: Ongoing

Dog, ['Ridgeback - Rhodesian', 'Dog (unknown)'], Female, 11 year, 34.019 kilogram • Drug: MSK, Tablet, chewable, Unknown • Reactions: Hind limb paralysis, Loss of appetite, Increased drinking, Death by euthanasia • Outcome: Euthanized

  • Report ID: USA-USFDACVM-2026-US-013958
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 34.019 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Tablet, chewable
Reactions Reported:
Hind limb paralysis Loss of appetite Increased drinking Death by euthanasia
Outcomes: Euthanized

Dog, Retriever - Labrador, Male, 5 year, 49.895 kilogram • Drug: MSK, Tablet, chewable, Unknown • Reactions: Diarrhea • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2026-US-014227
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 5.00 Year
  • Weight: 49.895 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Tablet, chewable
Reactions Reported:
Diarrhea
Outcomes: Outcome Unknown

Dog, Pit Bull, Female, 7 year, 36.106 kilogram • Drug: MSK, Tablet, chewable, Oral • Reactions: Vomiting, Diarrhea • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-012380
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 7.00 Year
  • Weight: 36.106 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
Reactions Reported:
Vomiting Diarrhea
Outcomes: Ongoing

Dog, Bulldog - French, Male, 11 month, 12.701 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 4.46 Milligram per kilogram, Frequency: 1 per day • Reactions: Vomiting, Bloody diarrhoea, Not eating, Elevated blood urea nitrogen, Elevated creatinine… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2026-US-008268
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 11.00 Month
  • Weight: 12.701 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
  • Dose: 4.46 Milligram per kilogram
  • Frequency: 1 per day
Reactions Reported:
Vomiting Bloody diarrhoea Not eating Elevated blood urea nitrogen Elevated creatinine Hyperphosphataemia
Outcomes: Outcome Unknown

Dog, ['Collie - Border', 'Dog (unknown)'], Female, 14.4 year, 27.578 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Infectious disease NOS, Low thyroxine, Elevated liver enzymes NOS, Head tilt - neurological disorder, Unsteady gait… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-006296
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 14.40 Year
  • Weight: 27.578 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Infectious disease NOS Low thyroxine Elevated liver enzymes NOS Head tilt - neurological disorder Unsteady gait Vestibular disorder NOS Loss of appetite Adipsia Horizontal nystagmus Sick euthyroid syndrome Neutrophilia
Outcomes: Ongoing

Dog, ['Retriever - Labrador', 'Poodle (unspecified)'], Female, 8 year, 31.751 kilogram • Drug: MSK, Tablet, Oral • Reactions: Tremor of limb, Unsteady gait, Torn ligament, Tendon rupture, Medication error NOS… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-006186
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 8.00 Year
  • Weight: 31.751 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
Reactions Reported:
Tremor of limb Unsteady gait Torn ligament Tendon rupture Medication error NOS Lameness
Outcomes: Ongoing

Dog, Saint Bernard Dog, Male, 10 year, 58.06 kilogram • Drug: MSK, Tablet, chewable, Unknown, Dose: 1 tablet per animal, Frequency: 1 per day • Reactions: Elevated blood urea nitrogen, Elevated creatinine • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-075505
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 10.00 Year
  • Weight: 58.060 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Tablet, chewable
  • Dose: 1 tablet per animal
  • Frequency: 1 per day
Reactions Reported:
Elevated blood urea nitrogen Elevated creatinine
Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.